comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Cardiovascular, mortality, receptor in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials glp-1 news today nov protocol:bariatric-regular Flavor:Blood Orange

comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Cardiovascular, mortality, receptor in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials glp-1 news today nov protocol:bariatric-regular Flavor:Blood Orange

glp-1 news today nov 2025 Medicare's New Pricing Initiative Signals a Shift in Coverage glp-1 news updates november 2025 –

For comparison, the SURMOUNT-1 trial for tirzepatide showed an average of 20.9% weight loss at the highest dose over 72 weeks

protocol:bariatric-regular

Flavor:Blood Orange

In the COR (Contrave Obesity Research) clinical trials, average weight loss was about 5-8% of body weight over 56 weeks